摘要
脑卒中后癫痫患者对低剂量抗癫痫发作药物治疗反应良好,但仍有部分患者进展为耐药性癫痫,因此亟待研发有效预防或逆转癫痫发生和发展且具备疾病修饰治疗作用的药物。业已证实,左乙拉西坦、拉莫三嗪、唑尼沙胺等新型抗癫痫发作药物,大麻二酚、多酚类化合物等天然化合物,线粒体抗氧化药、非甾体抗炎药等药物不仅能控制癫痫发作,甚至能够阻止脑卒中后癫痫的发生,以此发挥抗癫痫发生及疾病修饰治疗作用。本文对具有疾病修饰治疗作用的药物进行归纳,以为脑卒中后癫痫的疾病修饰治疗提供新的研究思路。
Post-stroke epilepsy(PSE)patients generally respond well to low-dose antiepileptic seizure medicine(ASM),but some patients still develop drug-resistant epilepsy(DRE).Thus,the development of effective drugs that can prevent or reverse epilepsy and disease modifying therapy(DMT)drugs are urgently needed.It was proved that new ASM such as levetiracetam(LVT),lamotrigine(LTG)and zonisamide,natural compounds such as cannabidiol and polyphenolic compounds,mitochondrial antioxidants and non-steroidal anti-inflammatory drug(NSAID)can not only control seizure but also intervene the occurrence of PSE,playing anti-epileptogenic and DMT role.This article intends to further summarize DMT drugs for PSE,providing new research ideas for PSE modifying therapy.
作者
徐莹
齐婧
王群
XU Ying;QI Jing;WANG Qun(Department of Epilepsy,Center of Neurology,Beijing Tiantan Hospital,Capital Medical University,China National Clinical Research Center for Neurological Diseases,Beijing 100070,China;Beijing Institute for Brain Disorders,Beijing 100069,China)
出处
《中国现代神经疾病杂志》
CAS
北大核心
2023年第3期167-172,共6页
Chinese Journal of Contemporary Neurology and Neurosurgery
基金
国家重点研发计划“常见多发病防治研究”重点专项(项目编号:2022YFC2503800)
北京市自然科学基金资助项目(项目编号:7232045)
北京市自然科学基金资助项目(项目编号:Z200024)
首都卫生发展科研专项(项目编号:2020-1-2013)。
